Transplantation of Adipose-Derived Stem Cells Before Flap Expansion and After Expanded Flap Elevation Result in Different Effects.
Wang Q., Hou S., Wang T., Guo X., Yu H., Wang J.
Animal Study, published in Ann Plast Surg (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Ann Plast Surg (2019)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 30628935
- DOI
- 10.1097/SAP.0000000000001736
Abstract (original English)
Background Studies of using mesenchymal stem cells to assist skin and soft tissue expansion have shown that stem cells can improve expansion efficiency through promoting tissue regeneration. However, the issue that whether the flap viability is also improved is unknown. Methods Sixteen pigs were equally divided into 2 groups. A pair of 150 mL expanders was symmetrically inserted into each pig's dorsum. Group 1 received adipose-derived stem cells (ADSCs) injection before expansion, and group 2 received ADSCs grafting after flap elevation. After 4 weeks' expansion, a random flap measuring 2 cm × 16 cm was elevated along the long axis of each expanded flap on the pigs' back. Flap viability was measured at postoperative day 7. Histological analysis and cell tracking were performed. The expression of vascular endothelial growth factor was determined. Results The flap viability of the ADSCs-grafted expanded flap (75.5 ± 6.6%) was similar to the control (69.4 ± 8.4%) in group 1 (transplantation before expansion). However, in group 2 (transplantation after flap elevation), the ADSCs-grafted expanded flap had a higher flap viability (92.6 ± 5.7%) compared with control (66.2 ± 7.4%). Moreover, the ADSCs-grafted expanded flap in group 1 showed increased skin thickness, collagen content, cells proliferation, vascularization, and vascular endothelial growth factor expression. Cell tracking
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.